The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials.

Citation metadata

Publisher: Frontiers Research Foundation
Document Type: Article
Length: 412 words
Lexile Measure: 2620L

Document controls

Main content

Article Preview :

Author(s): Cheng-Qiong Wang, Xiao-Tian Zheng, Xiao-Fan Chen, Hong Jiang, Jun Huang, Yuan Jiang, Shan-Shan Hu, Xiao-Rong Huang, Shi-Yu Liu, Qi-Hai Gong, Ji-Hong Feng, Xue Xiao, Xiao-Fei Li, Zheng Xiao

<bold>Introduction:</bold> Aidi injection (Aidi) is composed of cantharidin, astragaloside, ginsenoside, and elentheroside E. As an important adjuvant therapy, Aidi in combination with gemcitabine and cisplatin (GP) is often used in the treatment of non-small cell lung cancer (NSCLC).

<bold>Objectives:</bold> We performed a new evaluation to demonstrate the clinical efficacy and safety of the Aidi and GP combination and further explored an optimal strategy for achieving an ideal response and safety level in advanced NSCLC....

Source Citation

Source Citation   

Gale Document Number: GALE|A663437234